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Abstract
Parkinson’s disease (PD) was recently found to be associated with HLA in a genome-wide association study (GWAS). Follow-
up GWAS’s replicated the PD-HLA association but their top hits differ. Do the different hits tag the same locus or is there
more than one PD-associated variant within HLA? We show that the top GWAS hits are not correlated with each other
(0.00#r
2#0.15). Using our GWAS (2000 cases, 1986 controls) we conducted step-wise conditional analysis on 107 SNPs with
P,10
23 for PD-association; 103 dropped-out, four remained significant. Each SNP, when conditioned on the other three,
yielded PSNP1=5 610
24,P SNP2=5 610
24,P SNP3=4 610
23 and PSNP4=0.025. The four SNPs were not correlated
(0.01#r
2#0.20). Haplotype analysis (excluding rare SNP2) revealed increasing PD risk with increasing risk alleles from
OR=1.27, P=5610
23 for one risk allele to OR=1.65, P=4610
28 for three. Using additional 843 cases and 856 controls we
replicated the independent effects of SNP1 (Pconditioned-on-SNP4=0.04) and SNP4 (Pconditioned-on-SNP1=0.04); SNP2 and SNP3
could not be replicated. In pooled GWAS and replication, SNP1 had ORconditioned-on-SNP4=1.23, Pconditioned-on-SNP4=6 610
27;
SNP4 had ORconditioned-on-SNP1=1.18, Pconditioned-on-SNP1=3 610
23; and the haplotype with both risk alleles had OR=1.48,
P=2 610
212. Genotypic OR increased with the number of risk alleles an individual possessed up to OR=1.94, P=2610
211
for individuals who were homozygous for the risk allele at both SNP1 and SNP4. SNP1 is a variant in HLA-DRA and is
associated with HLA-DRA, DRB5 and DQA2 gene expression. SNP4 is correlated (r
2=0.95) with variants that are associated
with HLA-DQA2 expression, and with the top HLA SNP from the IPDGC GWAS (r
2=0.60). Our findings suggest more than one
PD-HLA association; either different alleles of the same gene, or separate loci.
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Introduction
The recent discovery of an association between PD and HLA was
made in a hypothesis neutral genome-wide association study
(GWAS) [1]. Historically, HLA-disease associations have been
conducted with the highly polymorphic ‘‘classical’’ HLA loci; i.e.,
those that encode the diversity for antigen recognition; whereas, the
association peakinourGWAS wasinHLA-DRAwhich is practically
monomorphic and hence not normally investigated for disease
associations. The finding that genetic variants in immune response
affect risk of developing PD, firmly grounds, at the DNA level, the
long held notion that the immune system and inflammation play a
significant role in PD [2].
Our original GWAS that uncovered an association between PD
and HLA was performed with the NeuroGenetic Research
Consortium (NGRC) data. NGRC is a single data set (2000 persons
with PD, 1986control volunteers) which wascollected using uniform
protocols for all study procedures including subject selection and
diagnosis, data collection, genotyping and data analysis [1]. The
NGRC GWAS revealed a spike at HLA for association with PD that
reached genome-wide significance. The association peak was at
rs3129882, a SNP in intron 1 of HLA-DRA which had previously
been shown to associate with variation in expression of HLA-DRA,
DRB5 and DQA2 [3,4]. Association of rs3129882 with PD had an
odds ratio (OR)=1.31, and P=3610
28 in discovery and was
replicated in independent datasets in the same study [1]. The HLA
region spike in the NGRC data included 107 SNPs that achieved P
values of 10
23 to 3610
28. A subsequent GWAS conducted in the
Dutch population (772 cases, 2024 controls) confirmed the
association of PD with HLA [5]. Their most significant SNP was
rs4248166: OR=1.36, P=4610
25 which also maps to the HLA
class II region. The involvement of the HLA region in PD was also
confirmed by the International Parkinson Disease Genomics
Consortium (IPDGC) meta-analysis [6], which identified
chr6:32588205 in the HLA class II region as the most significant
SNP in their discovery sample (5333 cases, 12019 controls) with
OR=0.70, P=3610
28 and in their replication sample (7053 cases,
9007 controls) OR=0.80, P=9610
28.
It is not unexpected that different GWAS’s are identify-
ing different HLA SNPs; arrays with different SNPs were used.
PLoS ONE | www.plosone.org 1 November 2011 | Volume 6 | Issue 11 | e27109However, do the different top SNPs from various studies all tag the
same locus or could there be more than one PD-associated
susceptibility variant in HLA? The aim of this study was to explore
this question.
Results
HLA hits in three GWAS’s
The most significant HLA SNPs from the three GWAS’s
including and subsequent to our original report are shown in
Table 1. They span a ,100 kb region in the HLA class II region.
We expected to find strong linkage disequilibrium (LD) (measured
by r
2, where r is the correlation coefficient) among them, assuming
all three are tagging the same PD-susceptibility locus. Surprisingly,
there was very little correlation between the SNPs as evidenced by
pair wise r
2=0.00, 0.09 and 0.15 (Figure 1).
Conditional analysis in NGRC GWAS
To gain a better understanding of the HLA association with PD,
we performed step-wise conditional analysis in the NGRC GWAS.
Conditional analysis allows testing all the SNPs in the region (or a
chosen subset, here according to statistical significance), to identify
the most significant one, and repeating the analysis conditioned on
the most significant SNP to see if others are significant in addition
to the top SNP [7,8,9]. The process is repeated, each time
conditioning on all SNPs that emerged as most significant in prior
rounds, until all SNPs whose significance is dependent on other
SNPs are identified and removed. We performed conditional
analysis on 107 HLA SNPs that had achieved P,0.001 for PD-
association in the NGRC GWAS [1], using PLINK v1.07 software
[10] (Table S1). In round 1, when analysis was performed
conditioned on the single most significant SNP (SNP1, rs3129882),
90 of 106 SNPs lost significance while 16 SNPs remained
significant at P,0.05. The SNP with the lowest P value
(rs3993757, P=0.002) was marked SNP2. When the analysis
was repeated (round two) conditioned on both SNP1 and SNP2
for the 15 SNPs that survived round one, 13 were associated with
PD with P,0.05, and the most significant SNP of this analysis
(rs2844505, P=0.006) was marked SNP3. When the analysis was
repeated with the 12 remaining SNPs conditioning now on SNP1
and SNP2 and SNP3 (round three), only one SNP had P,0.05
(rs9268515, P=0.025) and it was marked SNP4. Summary of the
results are shown in Table 2. For the full analysis see Table S1.
Step-wise conditional analysis revealed four HLA SNPs with
seemingly independent effects on PD. We re-tested association of
each of the four SNPs with PD conditioning on the other three. We
obtained P=5610
24 for SNP1 conditioned on SNP2 and SNP3 and
SNP4, P=5610
24 for SNP2 conditioned on SNP1 and SNP3
and SNP4, P=4610
23 for SNP3 conditioned on SNP1 and SNP2
and SNP4, and P=0.025 for SNP4 conditioned on SNP1 and
SNP2 and SNP3.
Interaction among SNPs 1–4 in NGRC
We tested for and did not find significant evidence for
interaction among the four SNPs. The full model testing all
pair-wise interactions among the four SNPs compared with a
model with no interactions yielded P=0.9. Testing each pair-wise
interaction, with all other SNPs in the model as covariates, yielded
P=0.2–0.7. Lack of evidence for interaction could have been due
to insufficient power (discussed further under Replication).
Linkage Disequilibrium
We examined LD between the four SNPs that withstood
conditional analysis. LD was measured as D9 and r
2 (correlation
coefficient) [11]. In the context of disease association, r
2 is
commonly used to assess correlation among SNPs (see for example
[8]). Using the NGRC data for estimating LD, pair-wise D9 for the
four NGRC SNPs ranged from 0.17 to 0.75 and r
2 ranged from
0.00 to 0.09. Using the 1000 Genomes Project data for estimating
LD (to allow inclusion of IPDGC SNP) the NGRC SNPs 1–4 had
D9=0 to 0.88 and r
2=0.01 to 0.20 (Figure 2). In relation to the
top SNPs from other GWAS’s (Figure 2), SNP1, SNP2, and SNP3
showed little or no correlation with them (0.00#r
2#0.15), whereas
SNP4 was moderately correlated with the top SNP from IPDGC
(r
2=0.60).
Haplotype analysis
We performed haplotype analysis for the SNPs that had
emerged from NGRC conditional analysis (SNP1, SNP3 and
SNP4; SNP2 was not included because its minor allele was rare
and none of the haplotypes carrying the minor allele of SNP2 had
Figure 1. Linkage disequilibrium (LD) among top HLA associ-
ations from three PD GWAS’s. LD was measured as D9 (panel A) and
as r
2 (panel B) among rs3129882 from the NGRC GWAS [1], rs4248166
from Dutch GWAS [5], and 6–32588205 from IPDGC meta analysis [6].
Numbers in cells are % D9 (panel A) and % r
2 (panel B). The red cells
with no number reflects D9=1.0.
doi:10.1371/journal.pone.0027109.g001
Table 1. HLA SNPs that have shown the most significant associations with PD in three GWAS’s.
GWAS
N
cases
N
controls SNP Gene BP
MAF
cases
MAF
controls OR P
NGRC [1] 2000 1986 rs3129882 DRA 32517508 0.46 0.40 1.31 3610
28
Dutch [5] 772 2024 rs4248166 BTNL2 32474399 0.21 0.17 1.36 4610
25
IPDGC [6] 5333 12019 chr6:32588205 39 of DRB5 32588205 (0.15 unspecified) 0.70 3610
28
doi:10.1371/journal.pone.0027109.t001
Multiple PD-HLA Associations
PLoS ONE | www.plosone.org 2 November 2011 | Volume 6 | Issue 11 | e27109a frequencyabove0.01)(Table3).Wesetthehaplotypethatcarries
the lower risk allele for each SNP (AAC) as the reference and
calculated relative effects of each haplotype on PD risk. (High risk
allelesareshowninbold foreaseofreading).Thehigh riskallelewas
the minor allele for SNP1 and SNP3, and the major allelefor SNP4.
The haplotype with the most significant association with PD was
GGG which has the high risk alleles at all three SNPs (OR=1.65,
95%CI=1.38–1.97, P=4610
28). The next most significant
haplotype was GAG with two high risk alleles at SNP1 and SNP4
(OR=1.57, 95%CI=1.32–1.86, P=2610
27), followed by AGG
with two high risk alleles at SNP3 and SNP4 (OR=1.56,
95%CI=1.22–1.99, P=4610
24), and then AAG with one high
risk allele at SNP4 (OR=1.27, 95%CI=1.07–1.50, P=5610
23).
GAChadthe highest OR estimate despite having the risk allele only
at SNP1 (OR=1.75, 95%CI=1.07–2.87, P=0.03); note however
that the confidence interval was large due to the low frequency of
this haplotype.
Replication
We attempted to replicate the following observations: (a) SNPs 1–
4 are associated with PD; (b) association of each SNP with PD
remains significant when conditioned on the other three SNPs; (c)
haplotype analyses will reveal similar pattern of increasing risk with
increasing risk alleles as seen in our NGRC results. We performed
the replication in an independent dataset (843 cases and 856
controls) that is published [12] and publicly available on the NIH
database of Genotypes and Phenotypes (dbGaP, accession number
phs000126.v1.p1).
We replicated the association of PD with SNP1 (rs3129882,
OR=1.20, P=0.006) and with SNP4 (rs9268515, OR=1.25,
P=0.004); SNP3 did not replicate (Table 4). SNP2 was not
genotyped in that dataset and could not be imputed. SNP1 and
SNP4 remained significant in replication when conditioned on each
other (SNP1 OR=1.15, P=0.04; SNP4 OR=1.19, P=0.04,
Table 4).
We performed haplotype analysis for SNP1 and SNP4. Since the
NGRC haplotype analysis was performed with three SNPs, for a
direct comparison, we repeated the NGRC haplotype analysis with
SNP1 and SNP4, leaving out SNP3. The NGRC and replication
haplotype analyses yielded similar results (Table 5), with the most
significant effect for the haplotype GG with two risk alleles
(ORNGRC=1.51, P NGRC=1 610
29,O R Replication=1.41, PReplication
=2 610
24,O R Pooled=1.48, P Pooled=2 610
212), followed by AG
(ORNGRC=1.23, P NGRC=3 610
23,O R Replication=1.28, PReplication
=0.01, ORPooled=1.25, PPooled=2 610
24); the results for GCa r el e s s
reliable due to the smaller sample size (Table 5).
Test of interaction between SNP1 and SNP4 in the combined
NGRC and replication data yielded ORInteraction=1.12, PInteraction
=0.19. If interaction exists, it is weak (ORinteraction,1.12) and would
require a larger sample size than available here to achieve significance.
Our power to detect ORinteraction=1.12withP=0.05was42%.We
had 80% power to detect ORinteraction$1.20, and 90% power to detect
ORinteraction$1.23, using the combined NGRC and replication data.
Therefore, we should have been able to detect interactions with
moderate or high magnitude.
The effects of SNP1 and SNP4 appeared to be additive, as
suggested by the OR for genotypic combinations, increasing
incrementally with the number of risk alleles an individual
possessed up to OR=1.94, P=2610
211 for individuals who were
homozygous for the risk allele at both SNP1 and SNP4 (Table 6).
Discussion
It is intriguing that different GWAS’s have identified different
SNPs as their top PD associated SNP in the HLA region. We
questioned whether they tag the same susceptibility locus. In this
study, we demonstrated that the top hits from different studies are
not strongly correlated with each other. Low correlation among
PD-associated SNPs does not rule out the possibility that they tag
the same locus, but it does raise the possibility that there may be
more than one PD signal in HLA. Using step-wise conditional
analyses on the NGRC data we uncovered four seemingly
independent signals for PD within the HLA region. There was
no correlation and no detectable interaction among the four
NGRC SNPs. Two of the four NGRC SNPs, rs3129882 (SNP1)
and rs9268515 (SNP4), were replicated in an independent dataset.
We have therefore demonstrated that there are at least two HLA-
PD associations that cannot be explained by LD. These signals
Table 2. Step-wise conditional analysis.
SNP BP
Minor/
Major
Allele
MAF
cases
MAF
controls
HWE
P
Unconditioned (GWAS
results for SNPs that
survived conditional
analysis, see Table S1
for full data)
Conditioned
on SNP1
Conditioned on
SNP1 & SNP2
Conditioned
on SNP1 &
SNP2 & SNP3
OR P OR P OR P OR P
SNP1 rs3129882 32517508 G/A 0.46 0.40 0.82 1.31 3610
28
SNP2 rs3993757 31698725 T/C 0.03 0.02 1.00 1.79 7610
24 1.70 2610
23
SNP3 rs2844505 31547042 G/A 0.29 0.25 0.01 1.23 9610
25 1.15 0.011 1.16 6610
23
SNP4 rs9268515 32487273 C/G 0.16 0.20 0.33 1.25 4610
24 1.14 0.049 1.16 0.028 1.16 0.025
Number of SNPs remaining significant at the end of each round 107 with P,10
23 in
GWAS (Table S1)
16 with P,0.05 13 with P,0.05 1 with P,0.05
Step-wise conditional analysis was performed for 107 SNPs in the HLA region that achieved P,10
23 in GWAS. The full analysis is shown in Table S1. Here, we show the
summary results for the four SNPs that remained significant after conditioning on the other significant SNPs. For consistency, we show all odds ratios (OR) on the
positive side (i.e., testing risk allele against the alternate allele). The risk allele at each SNP is shown in bold. All association tests were adjusted for age at enrollment, sex,
and PC1 and PC2 (principal components that define Jewish/non-Jewish origin and the European country of ancestry). Once the four SNPs that retain conditioned
P,0.05 were identified, we re-tested association of each of the SNPs with PD conditioning on the other three. We obtained P=5610
24 for SNP1 conditioned on SNP2
and SNP3 and SNP4, P=5610
24 for SNP2 conditioned on SNP1 and SNP3 and SNP4, P=4610
23 for SNP3 conditioned on SNP1 and SNP2 and SNP4, and P=0.025 for
SNP4 conditioned on SNP1 and SNP2 and SNP3. BP=base pair position of the SNP on chromosome 6. Minor/major allele=the two alternative nucleotides at theS N P ,
the one with higher frequency denoted as major allele. MAF=minor allele frequency. HWE P=P value for the test of Hardy-Weinberg Equilibrium.
doi:10.1371/journal.pone.0027109.t002
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gene, or different PD susceptibility loci. In support of the different
alleles in the same gene hypothesis, there are known examples of
multiple disease-associated alleles at the same gene for HLA-
associated diseases including type1 diabetes [13] and multiple
sclerosis [14], as well as multiple association signals for PD within
one gene, notably, SNCA [8,15]. Alternatively, the signals may
represent different genes. SNP1, rs3129882, the original genome-
wide significant finding in NGRC, is an expression quantitative trait
locus (eQTL). It is in intron 1 of HLA-DRA and is associated with
expression levels of HLA-DRA, DRB5 and DQA2 genes [3,4]. SNP4,
rs9268515, is highly correlated (r
2=0.95) with three eQTL SNPs
(rs3793127, rs3763309, rs3763312) that are associated with expres-
sion levels of HLA-DQA2 [4]. SNP4 also correlates with the top
SNP of IPDGC (r
2=0.60), which maps between DRA and DRB5,
and could be tagging any of the classical HLA genes in the DR-DQ
region due to their high LD. This raises the intriguing possibility
that PD may be associated with both regulatory elements that
influence HLA class II gene expression, and with a classical HLA class
II allele.
The allele frequency for SNP1 varies significantly in Caucasian
Americans according to the European country from which their
ancestors immigrated to the US [1]. Furthermore, SNP1 is more
strongly associated with sporadic PD than familial PD [1].
Therefore, depending on subject selection, a study may find a
positive association (as reported in NGRC), no association, or even
an inverse association between SNP1 and PD. We used principal
components to correct for ethnic and geographic variability. The
subpopulations that differed were the Jewish and the Irish (defined
by self-report and verified by principal components [1]). SNP1 and
SNP4 remained significant when we excluded the Jewish and the
Irish individuals. A recent study showed an inverse association
between SNP1 and PD in a mixed Irish and Polish population
[16]. It is noteworthy that in the original NGRC GWAS report
[1], the Americans of Irish-descent also showed an inverse
association between SNP1 and PD, while all other European-
descent subpopulations showed a positive association (number of
individuals of Polish-descent were few). The Irish/Polish study
found the association using a recessive model, as compared to
additive model used in NGRC. This is also in agreement with the
NGRC data, because the recessive model projects a larger effect
size than additive model because it compares individuals who are
homozygous for the risk allele to all others.
SNP2 and SNP3 are more than 800 kb away from SNP1 and
SNP4. SNP2 had a low minor allele frequency and thus could not
be studied in any detail. SNP3 indicated a potential third signal in
the NGRC data, but it did not replicate. Much larger sample sizes
will be required to determine if and how SNP2 and SNP3 affect
susceptibility to PD.
SNP4 was the last of the four seemingly independent SNPs to
show up in the conditional analysis of the NGRC data with a
modest P=0.025; and it was the only one of the four NGRC SNPs
that showed any correlation with the top HLA hit of IPDGC. The
direction of the SNP4 effect was the same as the IPDGC SNP;
they reported reduced risk with the minor allele, we report
increased risk with the major allele (we used the risk alleles
throughout the text and the main tables to keep the ORs
consistently in the positive direction). We used a liberal P,0.05
given the exploratory nature of the study and that we would follow
with a replication study. That our last significant HLA SNP tagged
the most significant HLA SNP in IPDGC gives credence to SNP4
being a true association rather than a false positive signal due to a
relaxed significance threshold. SNP4 was genotyped in NGRC
and imputed in the replication study. The Impute Information
score was 0.95, suggesting relatively high reliability. Cases and
controls were imputed together under the same conditions, using
the same method, and independently of NGRC, and the results
showed significantly different allele frequencies between cases and
controls for SNP4, in line with the original observation in NGRC.
Thus it is unlikely that the results for replication were severely
skewed by the fact that SNP4 was imputed; however, replication
by other studies will help clarify further.
Figure 2. LD among the four significant SNPs from NGRC
conditional analysis and the most significant HLA SNPs from
other PD GWAS’s. LD was measured as D9 (panel A) and as r
2 (panel
B). NGRC SNPs are numbered 1–4 and marked in red frame. The most
significant HLA SNP from other GWAS’s are indicated by rs number and
the study name. Numbers in cells are % D9 (panel A) and % r
2 (panel B).
Red cell without a number reflects D9=1, blue cells without a number
reflect D9=0.
doi:10.1371/journal.pone.0027109.g002
Multiple PD-HLA Associations
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individuals and perhaps little or no role for others. HLA may be
involved in a subtype of PD; for example, some cases of PD may be
due to infection [17] or autoimmunity [18]. Alternatively, HLA may
have a ubiquitous role in all PD perhaps via inflammatory response
to a variety of causes [19]. The two possibilities are not mutually
exclusive; i.e., it is possible that HLA and the immune system affect
PD pathogenesis in more than one way.
Our results illustrate the utility of conditional analyses and
examination of LD structure in replication studies. These explor-
atory studies can be used to investigate the possibility of more than
one disease association in a region. They can also help understand
the differences in the results across association studies. We
acknowledge the exploratory nature of this study and the difficulty
of deciphering HLA-disease association due to the complex structure
of the region. At this point, we have probably identified markers and
notthetrueriskalleles.Notonlyisitcriticaltounderstandthe nature
of the association(s) of PD with HLA, it is equally important to
understand the interrelationship between PD and other HLA-
associated disorders, particularly multiple sclerosis which like PD is a
neurodegenerative disorder [14,20,21,22]. Solving this evolving
story will take open collaboration to amass large datasets with
genotype, sequence, expression and epigenetic data.
Materials and Methods
Human Subjects
This study was approved by the Institutional Review Boards of
the New York State Department of Health, Emory University and
Atlanta VA Medical Center, VA Puget Sound Heath Care System
and University of Washington, and Albany Medical College. All
participants gave consent. The majority was signed written
consent. A subset of participants who preferred to remain
anonymous gave verbal consent. Both written and verbal consent
procedures were approved by the IRBs and documented in each
participant’s data file. A GWAS conducted with 2000 cases and
1986 controls from the NGRC, which had previously identified
HLA as a PD-associated gene [1] was examined as the primary
dataset here. Persons with PD had been diagnosed using standard
criteria [23]. Cases and controls were unrelated, non-Hispanic
Caucasians from the United States. (See below for Replication
dataset.)
Genotyping
DNA was obtained from whole blood for NGRC subjects, and
from blood, cell lines, or whole genome amplified DNA for the
replication dataset. NGRC individuals were genotyped using the
Illumina HumanOmni1-Quad_v1-0_B array, with a call rate of
99.92% and 99.99% reproducibility. Details of the GWAS
genotyping and statistical quality control (QC) have been previously
published [1]. 9,232 SNPs were genotyped in the HLA region in
NGRC (from 29–33 Mb on chromosome 6; genome build 36).
Quality Control for NGRC GWAS
NGRC genome-wide genotypes had previously been filtered
based on standard QC criteria [1]. Twoprincipal components (PC1
and PC2) were found to associate significantly with PD, represent-
ing Jewish/non-Jewish ancestry and European countries of
ancestral origin. Sex also significantly associated with case/control
status because PD is more prevalent in men than in women, and the
population used in this study reflects that disparity. Furthermore,
while controls in NGRC were intentionally selected to be older than
patients’ ageat onset,ageeffectsarenotcompletely correctedbythe
study design. Thus, all association tests with NGRC data included
age at enrollment, sex, PC1, and PC2 as covariates.
Step-wise conditional Analysis
The step-wise conditioning followed a previously described and
commonly used protocol [7], with the modification that here we
used logistic regression instead of chi-square and adjusted for
covariates (sex, age, PC1, PC2). We used 107 HLA SNPS that
reached P,0.001 in GWAS. For round 1 of the conditional
analysis, all 107 SNPs were ranked by P value. The SNP with
lowest P value was marked as SNP1. The remaining 106 SNPs
were tested for association with PD risk conditioned on SNP1. The
SNP with the lowest P value was marked SNP2, and analysis was
repeated now conditioning on SNP1 and SNP2. The process was
repeated until no remaining SNPs had P,0.05 for association with
PD. We chose to use P,0.05, rather than a more stringent
threshold, because the study was exploratory and would be
followed with replication.
Linkage Disequilibrium
We used Haploview [24] to construct haplotypes, visualize
haploblocks, and estimate LD and r
2. Since not all of the SNPs
Table 3. Haplotype analysis.
Haplotypes SNP1 (rs3129882)
SNP3 (rs2844505) SNP4 (rs9268515)
Freq.
Cases
Freq.
Controls OR (95% CI) P
AAC 0.11 0.15 Reference
AAG 0.33 0.36 1.27 (1.07–1.50) 5610
23
AGC 0.03 0.03 1.34 (0.93–1.91) 0.11
GAC 0.02 0.01 1.75 (1.07–2.87) 0.03
AGG 0.07 0.06 1.56 (1.22–1.99) 4610
24
GGC 0.006 0.007 - -
GAG 0.26 0.23 1.57 (1.32–1.86) 2610
27
GGG 0.18 0.15 1.65 (1.38–1.97) 4610
28
Haplotypes were composed of SNP1, SNP3 and SNP4, shown in that order. These SNPs and SNP2 survived conditional analysis at P,0.05. SNP2 had low frequency and
any haplotype with minor allele of SNP2 was too infrequent (,0.01) to be included in haplotype association tests. For each SNP, the allele that was associated with
higher risk for PD (see Table 2) is shown in bold. OR and P values were calculated for each haplotype relative to AAC haplotype which has the lowest risk for PD.
Analyses were adjusted for age at enrollment, sex, PC1, and PC2 (principal components that define Jewish/non-Jewish origin and the European country of ancestry).
AAG consists of major alleles for each SNP; GGC consists of minor alleles for each SNP. Haplotype GGC was not tested because its frequency was ,0.01.
doi:10.1371/journal.pone.0027109.t003
Multiple PD-HLA Associations
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LD was calculated using genotypes from the 1000 Genomes
Project [25]. SNP genotypes were downloaded from the 1000
Genomes Project website (www.1000genomes.org; CEU low
coverage, July 2010 release).
Haplotype Analysis
We used HAPSTAT-3.0 [26] to construct the haplotypes,
estimate haplotype frequencies for the top associating SNPs and
test haplotype association with PD, while adjusting for age, sex,
PC1 and PC2. Only haplotypes with frequencies of $0.01 in cases
and controls combined were included.
Replication
The dataset for replication was downloaded from dbGaP with IRB
approval and Data Use Certification from the National Institute of
Neurological Disorders and Stroke (NINDS) ((http://www.ncbi.nlm.
nih.gov/sites/entrez?db=gap) accession number phs000126.v1.p1).
The replication dataset was a single GWAS with843 persons with PD
collected by the PROGENI and GenePD studies and 856 neuro-
normal controls from the NINDS Repository [12]. Cases were
familial PD (one individual per family). Diagnosis was made using
standard criteria. Cases and controls were Caucasian and unrelated.
SNP1 (rs3129882) and SNP3 (rs2844505) were genotyped. We
imputed SNP4 (rs9268515) with information score=0.95. SNP2 was
not genotyped and did not impute. IMPUTE v2 [27] was used with
HapMap 3 and 1000 Genomes Project genotypes as reference data.
Genotypeprobabilities(dose2-0)wereanalyzedinRsoftwarehttp://
www.r-project.org/.Haplotypeanalyseswereperformedasdescribed
above. P values were one-sided for replication given the directional
hypotheses [28]. The pooled analyses of NGRC and replication
had two-sided P values and were adjusted for study as wellas age and
sex.
Interaction
The full model for testing all pair-wise interactions among the four
SNPs in NGRC was [SNP1+SNP2+SNP3+SNP4+SNP1*SNP2+S
NP1*SNP3+SNP1*SNP4+SNP2*SNP3+SNP2*SNP4+SNP3*SNP4+
covariates] vs. [SNP1+SNP2+SNP3+SNP4+covariates]. We also tested
each pair of SNPs one at a time, while keeping all other SNPs in the
model as covariates. For example, for interaction between SNP1 and
SNP2 the model was [SNP1*SNP2+SNP1+SNP2+SNP3+SNP4
+covariates].Allanalysesincluded thefollowingcovariates:sex,age,
PC1 and PC2. In the pooled dataset (NGRC plus replication), we
tested for interaction between SNP1 and SNP4 only as [SNP1*SNP4+
SNP1+SNP4+covariates]; here the covariates were age and sex. Power
calculation for interaction was performed using Quanto v1.2.4 [29]
with 2843 cases and 2842 controls and a two-sided a=0.05toestimate
power of our study to detect the observed interaction OR, and to
estimate the minimum interaction OR detectable with 80% or 90%
power.
Data access
NGRC data are available at www.ncbi.nlm.nih.gov/gap study
accession number phs000196.v2.p1. The replication dataset was
obtained from the NINDS Database found at (http://www.ncbi.
nlm.nih.gov/sites/entrez?db=gap) through dbGaP accession num-
ber phs000126.v1.p1.
Supporting Information
Table S1 Step-wise conditional analysis including 107
HLA SNPs that achieved P,10
23 in GWAS.
(PDF)
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